



## Nicox provides information on approval of Acieux patents in the United States

October 9, 2014.

Sophia Antipolis, France.

**Nicox S.A.** (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has been informed by Acieux Therapeutics, Inc. that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a U.S. Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions. With these new patents, AC-170 and AC-155 will have patent protection through March 15, 2030 and January 7, 2033, respectively. For more information, please see the [Acieux press release dated October 8, 2014](#).

Acieux is a private, US-based ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. On July 1, 2014, Nicox signed an agreement to acquire Acieux, for more information, see the [Nicox press release dated July 2, 2014](#) and the 'Document E' registered with the French *Autorité des Marchés Financiers* (AMF) on September 30, 2014 (E.14-060) (in French, available on Nicox's website [www.nicox.com](http://www.nicox.com) in the 'Investor Information' / 'Shareholder meetings' section).

### About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit [www.nicox.com](http://www.nicox.com).



This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4<sup>th</sup> chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2<sup>nd</sup>, 2014, in the "Rapport semestriel financier et d'activité au 30 juin 2014" and in the 5<sup>th</sup> chapter of the "Actualisation du Document de Référence 2013" filed on September 30, 2014 (D. 14-0271-A01), available on Nicox's website ([www.nicox.com](http://www.nicox.com)).

.....

<b>Contacts</b>		
<b>Nicox</b>	<b>Gavin Spencer   Executive Vice President Corporate Development</b> +33 (0)4 97 24 53 00   <a href="mailto:communications@nicox.com">communications@nicox.com</a>	
<b>Media Relations</b>		
<b>United Kingdom</b>	<b>Jonathan Birt</b> +44 7860 361 746   <a href="mailto:jonathan.birt@ymail.com">jonathan.birt@ymail.com</a>	
<b>France</b>	<b>Caroline Courme   Communication Manager</b> +33 (0)4 97 24 53 43   <a href="mailto:courme@nicox.com">courme@nicox.com</a>	